Investigational Drug Information for neflamapimod
✉ Email this page to a colleague
What is the drug development status for neflamapimod?
neflamapimod is an investigational drug.
There have been 5 clinical trials for neflamapimod.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 29th 2017.
The most common disease conditions in clinical trials are Dementia, Alzheimer Disease, and Lewy Body Disease. The leading clinical trial sponsors are EIP Pharma Inc, Worldwide Clinical Trials, and EIP Pharma, LLC.
There are sixteen US patents protecting this investigational drug and two hundred and eighty international patents.
Summary for neflamapimod
| US Patents | 16 |
| International Patents | 280 |
| US Patent Applications | 202 |
| WIPO Patent Applications | 65 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 2 (2017-12-29) |
| Vendors | 66 |
Recent Clinical Trials for neflamapimod
| Title | Sponsor | Phase |
|---|---|---|
| Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | National Institute on Aging (NIA) | Phase 2 |
| Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | Worldwide Clinical Trials | Phase 2 |
| Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | EIP Pharma Inc | Phase 2 |
Clinical Trial Summary for neflamapimod
Top disease conditions for neflamapimod
Top clinical trial sponsors for neflamapimod
US Patents for neflamapimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| neflamapimod | ⤷ Sign Up | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (Brisbane, CA) | ⤷ Sign Up |
| neflamapimod | ⤷ Sign Up | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (Basel, CH) | ⤷ Sign Up |
| neflamapimod | ⤷ Sign Up | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (Cambridge, MA) | ⤷ Sign Up |
| neflamapimod | ⤷ Sign Up | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (Braunschweig, DE) | ⤷ Sign Up |
| neflamapimod | ⤷ Sign Up | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (Basel, CH) | ⤷ Sign Up |
| neflamapimod | ⤷ Sign Up | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. Lundbeck A/S (Valby, DK) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for neflamapimod
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| neflamapimod | Australia | AU2006244072 | 2025-05-10 | ⤷ Sign Up |
| neflamapimod | Brazil | BRPI0608907 | 2025-05-10 | ⤷ Sign Up |
| neflamapimod | Canada | CA2608116 | 2025-05-10 | ⤷ Sign Up |
| neflamapimod | China | CN101237869 | 2025-05-10 | ⤷ Sign Up |
| neflamapimod | China | CN103012254 | 2025-05-10 | ⤷ Sign Up |
| neflamapimod | Cyprus | CY1115795 | 2025-05-10 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
